Recently, a phase 1/2 clinical trial demonstrated that Ibrutinib produces partial or complete responses in ABC DLBCL patients that rely on chronic BCR signaling, but is ineffective in patients carrying activating CARMA1/CARD11 mutations [11]. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.